Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $33.8100 (-0.18%) ($32.7200 - $35.3200) on Mon. Feb. 12, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.72% (three month average) | RSI | 24 | Latest Price | $33.8100(-0.18%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.4% a day on average for past five trading days. | Weekly Trend | ADMS declines -7.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(25%) IBB(23%) QQQ(19%) ARKK(18%) IWC(18%) | Factors Impacting ADMS price | ADMS will decline at least -1.86% in a week (0% probabilities). VIXM(-13%) UNG(-10%) BNDX(-9%) UUP(-8%) TLT(-7%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.86% (StdDev 3.72%) | Hourly BBV | 0 () | Intraday Trend | -2% | | | |
|
Resistance Level | $37.73 | 5 Day Moving Average | $35.21(-3.98%) | 10 Day Moving Average | $36.1(-6.34%) | 20 Day Moving Average | $37.73(-10.39%) | To recent high | -20.7% | To recent low | 28.5% | Market Cap | $956m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |